急性虚血性脳卒中の診断と治療市場：タイプ別、エンドユーザー別：世界の機会分析と産業予測、2023-2032年

急性虚血性脳卒中（AIS）の診断と治療市場は、2022年に51億米ドルと評価され、2023年から2032年にかけてCAGR 6.1%で成長し、2032年には92億米ドルに達すると予測されます。

急性虚血性脳卒中の診断と治療市場は、ヘルスケア部門からの診断技術に対する需要の増加により、2023年から2032年にかけて6.1%の大幅な成長率を記録する可能性が高いです。

急性虚血性脳卒中（AIS）は、死亡原因の第4位であり、成人障害の主な原因でもあります。この疾患は通常、血管の閉塞が起こり、不可逆的な脳損傷とそれに続く局所的な神経障害が生じたときに発生します。AISを治療する薬理学的アプローチは、遺伝子組換え型組織プラスミノーゲン活性化因子（tPA）としても知られるアルテプラーゼを用いた静脈内血栓溶解療法を中心に展開されます。アルテプラーゼの静脈内投与は、プラスミノーゲンの加水分解を触媒し、蛋白分解酵素プラスミンを形成することにより、血栓溶解を促進します。

急性虚血性脳卒中の診断と治療市場は、虚血性脳卒中の有病率の上昇により大きな成長を遂げています。例えば、World Stroke Organization Global Stroke Fact Sheet 2022によると、毎年760万件以上の虚血性脳卒中が新たに発生しており、世界全体では全発生脳卒中の62％以上が虚血性脳卒中です。

しかし、虚血性脳卒中の診断と治療には高い費用がかかるため、市場の成長は限られています。例えば、世界脳卒中機構（WSO）によると、Lancet Public Healthの論文では、脳卒中の治療、リハビリテーション、間接的なコストは年間7,000億米ドル以上と推定されています。このように、高い診断・治療費は市場成長にマイナスの影響を与えます。

一方、以下のような血栓溶解薬を含む治療オプションの進歩が続いています。

• アルテプラーゼや血栓除去術のような革新的な機械的介入を含む治療オプションの継続的な進歩が、急性虚血性脳卒中市場の成長を後押ししています。これらの開発は、急性虚血性脳卒中の効果的かつタイムリーな管理に貢献しています。

急性虚血性脳卒中の診断と治療市場は、タイプ、エンドユーザー、地域に区分されます。タイプ別では、市場は診断と治療に分類されます。診断分野はさらに、コンピューター断層撮影、磁気共鳴画像、頸動脈超音波、脳血管撮影、心電図、心エコー、その他に分類されます。治療セグメントは血栓溶解療法と機械的血栓除去術に二分されます。血栓溶解療法はさらに、組織プラスミノーゲン活性化薬、抗血小板薬、その他の活動に分類されます。機械的血栓除去術のセグメントは、ステントリトリーバーと吸引カテーテル、およびコンビネーション（ステントリトリーバーと吸引カテーテル）に分類されます。エンドユーザー別では、病院・診療所、診断研究所・画像診断センター、その他に分類されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

• 市場の定義と範囲
• 主な調査結果
  • 影響要因
  • 主な投資機会
• ポーターのファイブフォース分析
• 市場力学
  • 促進要因
    • 脳卒中発症率の増加
    • 画像技術の進歩
    • 治療オプションの革新
  • 抑制要因
    • 革新的治療法の高コスト
  • 機会
    • 新興市場における高い市場成長の可能性

第4章 急性虚血性脳卒中の診断と治療市場：タイプ別

• 概要
• 診断薬
• 治療

第5章 急性虚血性脳卒中の診断と治療市場：エンドユーザー別

• 概要
• 病院および診療所
• 外来手術センター
• 診断研究所および画像診断センター
• その他

第6章 急性虚血性脳卒中の診断と治療市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • その他
• ラテンアメリカ・中東・アフリカ
  • ブラジル
  • サウジアラビア
  • 南アフリカ
  • その他

第7章 競合情勢

• イントロダクション
• 主要成功戦略
• 主要10社の製品マッピング
• 競合ダッシュボード
• 競合ヒートマップ
• 主要企業のポジショニング、2022年

第8章 企業プロファイル

• AstraZeneca plc
• F. Hoffmann-La Roche Ltd.
• GE Healthcare
• Boehringer Ingelheim International GmbH
• Koninklijke Philips N.V.
• Abbott Laboratories
• Siemens
• Medtronic plc
• Johnson & Johnson
• Stryker Corporation.

LIST OF TABLES

• TABLE 01. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 02. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR DIAGNOSTICS, BY REGION, 2022-2032 ($MILLION)
• TABLE 03. GLOBAL DIAGNOSTICS ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
• TABLE 04. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR TREATMENT, BY REGION, 2022-2032 ($MILLION)
• TABLE 05. GLOBAL TREATMENT ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 06. GLOBAL THROMBOLYTIC THERAPY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 07. GLOBAL MECHANICAL THROMBECTOMY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 08. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 09. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
• TABLE 10. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2022-2032 ($MILLION)
• TABLE 11. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR DIAGNOSTIC LABORATORIES AND IMAGING CENTERS, BY REGION, 2022-2032 ($MILLION)
• TABLE 12. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
• TABLE 13. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
• TABLE 14. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 15. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 16. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 17. U.S. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 18. U.S. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 19. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 20. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 21. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 22. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 23. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 24. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 25. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 26. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 27. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 28. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 29. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 30. UK ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 31. UK ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 32. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 33. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 34. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 35. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 36. REST OF EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 37. REST OF EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 38. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 39. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 40. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 41. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 42. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 43. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 44. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 45. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 46. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 47. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 48. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 49. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 50. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 51. REST OF ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 52. REST OF ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 53. LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 54. LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 55. LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 56. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 57. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 58. SAUDI ARABIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 59. SAUDI ARABIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 60. SOUTH AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 61. SOUTH AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 62. REST OF LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 63. REST OF LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 64. ASTRAZENECA PLC: KEY EXECUTIVES
• TABLE 65. ASTRAZENECA PLC: COMPANY SNAPSHOT
• TABLE 66. ASTRAZENECA PLC: PRODUCT SEGMENTS
• TABLE 67. ASTRAZENECA PLC: PRODUCT PORTFOLIO
• TABLE 68. ASTRAZENECA PLC: KEY STRATERGIES
• TABLE 69. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
• TABLE 70. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
• TABLE 71. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
• TABLE 72. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
• TABLE 73. GE HEALTHCARE: KEY EXECUTIVES
• TABLE 74. GE HEALTHCARE: COMPANY SNAPSHOT
• TABLE 75. GE HEALTHCARE: PRODUCT SEGMENTS
• TABLE 76. GE HEALTHCARE: SERVICE SEGMENTS
• TABLE 77. GE HEALTHCARE: PRODUCT PORTFOLIO
• TABLE 78. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
• TABLE 79. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
• TABLE 80. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
• TABLE 81. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
• TABLE 82. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
• TABLE 83. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
• TABLE 84. KONINKLIJKE PHILIPS N.V.: PRODUCT SEGMENTS
• TABLE 85. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
• TABLE 86. KONINKLIJKE PHILIPS N.V.: KEY STRATERGIES
• TABLE 87. ABBOTT LABORATORIES: KEY EXECUTIVES
• TABLE 88. ABBOTT LABORATORIES: COMPANY SNAPSHOT
• TABLE 89. ABBOTT LABORATORIES: PRODUCT SEGMENTS
• TABLE 90. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
• TABLE 91. SIEMENS: KEY EXECUTIVES
• TABLE 92. SIEMENS: COMPANY SNAPSHOT
• TABLE 93. SIEMENS: PRODUCT SEGMENTS
• TABLE 94. SIEMENS: PRODUCT PORTFOLIO
• TABLE 95. SIEMENS: KEY STRATERGIES
• TABLE 96. MEDTRONIC PLC: KEY EXECUTIVES
• TABLE 97. MEDTRONIC PLC: COMPANY SNAPSHOT
• TABLE 98. MEDTRONIC PLC: PRODUCT SEGMENTS
• TABLE 99. MEDTRONIC PLC: PRODUCT PORTFOLIO
• TABLE 100. JOHNSON & JOHNSON: KEY EXECUTIVES
• TABLE 101. JOHNSON & JOHNSON: COMPANY SNAPSHOT
• TABLE 102. JOHNSON & JOHNSON: PRODUCT SEGMENTS
• TABLE 103. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
• TABLE 104. STRYKER CORPORATION.: KEY EXECUTIVES
• TABLE 105. STRYKER CORPORATION.: COMPANY SNAPSHOT
• TABLE 106. STRYKER CORPORATION.: PRODUCT SEGMENTS
• TABLE 107. STRYKER CORPORATION.: PRODUCT PORTFOLIO

LIST OF FIGURES

• FIGURE 01. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032
• FIGURE 02. SEGMENTATION OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET,2022-2032
• FIGURE 03. TOP IMPACTING FACTORS IN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET (2022 TO 2032)
• FIGURE 04. TOP INVESTMENT POCKETS IN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET (2023-2032)
• FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
• FIGURE 06. LOW THREAT OF NEW ENTRANTS
• FIGURE 07. LOW THREAT OF SUBSTITUTES
• FIGURE 08. LOW INTENSITY OF RIVALRY
• FIGURE 09. LOW BARGAINING POWER OF BUYERS
• FIGURE 10. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
• FIGURE 11. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE, 2022 AND 2032(%)
• FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR DIAGNOSTICS, BY COUNTRY 2022 AND 2032(%)
• FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR TREATMENT, BY COUNTRY 2022 AND 2032(%)
• FIGURE 14. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2022 AND 2032(%)
• FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
• FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY 2022 AND 2032(%)
• FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR DIAGNOSTIC LABORATORIES AND IMAGING CENTERS, BY COUNTRY 2022 AND 2032(%)
• FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
• FIGURE 19. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET BY REGION, 2022 AND 2032(%)
• FIGURE 20. U.S. ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 21. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 22. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 23. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 24. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 25. UK ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 26. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 27. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 28. REST OF EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 29. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 30. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 31. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 32. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 33. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 34. REST OF ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 35. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 36. SAUDI ARABIA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 37. SOUTH AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 38. REST OF LAMEA ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 39. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
• FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
• FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
• FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
• FIGURE 43. COMPETITIVE DASHBOARD
• FIGURE 44. COMPETITIVE HEATMAP: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET
• FIGURE 45. TOP PLAYER POSITIONING, 2022
• FIGURE 46. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
• FIGURE 47. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 48. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
• FIGURE 49. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 50. GE HEALTHCARE: NET REVENUE, 2021-2022 ($MILLION)
• FIGURE 51. GE HEALTHCARE: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 52. GE HEALTHCARE: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 53. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION)
• FIGURE 54. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 55. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 56. KONINKLIJKE PHILIPS N.V.: NET SALES, 2020-2022 ($MILLION)
• FIGURE 57. KONINKLIJKE PHILIPS N.V.: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
• FIGURE 58. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 59. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 60. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
• FIGURE 61. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 62. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 63. SIEMENS: NET REVENUE, 2020-2022 ($MILLION)
• FIGURE 64. SIEMENS: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
• FIGURE 65. SIEMENS: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 66. SIEMENS: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 67. MEDTRONIC PLC: NET SALES, 2021-2023 ($MILLION)
• FIGURE 68. MEDTRONIC PLC: REVENUE SHARE BY SEGMENT, 2023 (%)
• FIGURE 69. MEDTRONIC PLC: REVENUE SHARE BY REGION, 2023 (%)
• FIGURE 70. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
• FIGURE 71. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 72. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 73. STRYKER CORPORATION.: NET REVENUE, 2020-2022 ($MILLION)
• FIGURE 74. STRYKER CORPORATION.: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 75. STRYKER CORPORATION.: REVENUE SHARE BY REGION, 2022 (%)

According to a new report published by Allied Market Research, titled, "Acute Ischemic Stroke Diagnosis and Treatment Market," The acute ischemic stroke diagnosis and treatment market was valued at $5.1 billion in 2022, and is estimated to reach $9.2 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032. The Acute Ischemic Stroke Diagnosis and Treatment Market is likely to experience a significant growth rate of 6.1% from 2023-2032 owing to increase in demand for diagnostic technology from healthcare sector - Allied Market Research

Acute ischemic stroke (AIS) stands as the fourth leading cause of death and the primary cause of adult disability. This condition typically arises when a blood vessel obstruction occurs, resulting in irreversible brain injury and subsequent focal neurological deficits. The pharmacological approach to treating AIS revolves around intravenous thrombolysis using an alteplase, also known as recombinant tissue plasminogen activator (tPA). Alteplase administered intravenously facilitates thrombolysis by catalyzing the hydrolysis of plasminogen, forming the proteolytic enzyme plasmin.

The acute ischemic stroke diagnosis and treatment market has experienced significant growth owing to rise in prevalence of ischemic stroke. For instance, according to the World Stroke Organization Global Stroke Fact Sheet 2022, there were over 7.6 million new ischemic strokes each year and globally, over 62% of all incident strokes are ischemic strokes.

However, high cost of ischemic stroke diagnosis and treatment limits the market growth. For instance, according to World Stroke Organization (WSO), the Lancet Public Health article estimated treatment, rehabilitation, and indirect costs for stroke is more than $700 billion annually. Thus, high diagnosis and treatment cost negatively impact the market growth.

On the other hand, ongoing advancements in treatment options, including thrombolytic medications such as alteplase and innovative mechanical interventions like thrombectomy, drive the growth of the acute ischemic stroke market. These developments contribute to effective and timely management of acute ischemic strokes.

The acute ischemic stroke diagnosis and treatment market is segmented into type, end user, and region. By type, the market is segregated into diagnosis, and treatment. The diagnosis segment is further categorized into computed tomography, magnetic resonance imaging, carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others. The treatment segment is bifurcated into thrombolytic therapy and mechanical thrombectomy. The thrombolytic therapy segment is further classified into tissue plasminogen activator, antiplatelet, and others. The mechanical thrombectomy segment is categorized into stent retriever and aspiration catheter, and combination (stent retriever and aspiration catheter). By end user, the market is divided into hospitals & clinics, diagnostic laboratories & diagnostic imaging centers, and others.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).

Major key players that operate in the acute ischemic stroke diagnosis and treatment market are AstraZeneca plc, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, GE Healthcare, Koninklijke Philips N.V., Siemens, Abbott Laboratories Medtronic plc, Johnson & Johnson, and Stryker Corporation. Key players have adopted product approval, partnership, and agreement as key developmental strategies to improve the product portfolio of the acute ischemic stroke diagnosis and treatment market.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the acute ischemic stroke diagnosis and treatment market analysis from 2022 to 2032 to identify the prevailing acute ischemic stroke diagnosis and treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the acute ischemic stroke diagnosis and treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global acute ischemic stroke diagnosis and treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

• Diagnostics
  • Technology
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Carotid Ultrasound
  • Cerebral Angiography
  • Electrocardiography
  • Echocardiography
  • Others
• Treatment
  • Type
  • Thrombolytic Therapy

Type

• Mechanical Thrombectomy

Type

By End User

• Hospitals and Clinics
• Ambulatory Surgery Centers
• Diagnostic Laboratories and Imaging Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Boehringer Ingelheim International GmbH
• AstraZeneca plc
• Abbott Laboratories
• Stryker Corporation.
• Siemens
• Medtronic plc
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Koninklijke Philips N.V.
• GE Healthcare

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Increase in incidence of stroke
    • 3.4.1.2. Advancements in imaging technologies
    • 3.4.1.3. Innovations in treatment option
  • 3.4.2. Restraints
    • 3.4.2.1. High cost of innovative therapies
  • 3.4.3. Opportunities
    • 3.4.3.1. High market growth potential in emerging markets

CHAPTER 4: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Diagnostics
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
  • 4.2.4. Diagnostics Acute Ischemic Stroke Diagnosis and Treatment Market by Technology
• 4.3. Treatment
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
  • 4.3.4. Treatment Acute Ischemic Stroke Diagnosis and Treatment Market by Type
    • 4.3.4.1. Thrombolytic Therapy Acute Ischemic Stroke Diagnosis and Treatment Market by Type
    • 4.3.4.2. Mechanical Thrombectomy Acute Ischemic Stroke Diagnosis and Treatment Market by Type

CHAPTER 5: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Hospitals and Clinics
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Ambulatory Surgery Centers
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Diagnostic Laboratories and Imaging Centers
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Others
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY REGION

• 6.1. Overview
  • 6.1.1. Market size and forecast By Region
• 6.2. North America
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by Type
  • 6.2.3. Market size and forecast, by End User
  • 6.2.4. Market size and forecast, by country
    • 6.2.4.1. U.S.
    • 6.2.4.1.1. Market size and forecast, by Type
    • 6.2.4.1.2. Market size and forecast, by End User
    • 6.2.4.2. Canada
    • 6.2.4.2.1. Market size and forecast, by Type
    • 6.2.4.2.2. Market size and forecast, by End User
    • 6.2.4.3. Mexico
    • 6.2.4.3.1. Market size and forecast, by Type
    • 6.2.4.3.2. Market size and forecast, by End User
• 6.3. Europe
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by Type
  • 6.3.3. Market size and forecast, by End User
  • 6.3.4. Market size and forecast, by country
    • 6.3.4.1. Germany
    • 6.3.4.1.1. Market size and forecast, by Type
    • 6.3.4.1.2. Market size and forecast, by End User
    • 6.3.4.2. France
    • 6.3.4.2.1. Market size and forecast, by Type
    • 6.3.4.2.2. Market size and forecast, by End User
    • 6.3.4.3. UK
    • 6.3.4.3.1. Market size and forecast, by Type
    • 6.3.4.3.2. Market size and forecast, by End User
    • 6.3.4.4. Italy
    • 6.3.4.4.1. Market size and forecast, by Type
    • 6.3.4.4.2. Market size and forecast, by End User
    • 6.3.4.5. Spain
    • 6.3.4.5.1. Market size and forecast, by Type
    • 6.3.4.5.2. Market size and forecast, by End User
    • 6.3.4.6. Rest of Europe
    • 6.3.4.6.1. Market size and forecast, by Type
    • 6.3.4.6.2. Market size and forecast, by End User
• 6.4. Asia-Pacific
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by Type
  • 6.4.3. Market size and forecast, by End User
  • 6.4.4. Market size and forecast, by country
    • 6.4.4.1. Japan
    • 6.4.4.1.1. Market size and forecast, by Type
    • 6.4.4.1.2. Market size and forecast, by End User
    • 6.4.4.2. China
    • 6.4.4.2.1. Market size and forecast, by Type
    • 6.4.4.2.2. Market size and forecast, by End User
    • 6.4.4.3. India
    • 6.4.4.3.1. Market size and forecast, by Type
    • 6.4.4.3.2. Market size and forecast, by End User
    • 6.4.4.4. Australia
    • 6.4.4.4.1. Market size and forecast, by Type
    • 6.4.4.4.2. Market size and forecast, by End User
    • 6.4.4.5. South Korea
    • 6.4.4.5.1. Market size and forecast, by Type
    • 6.4.4.5.2. Market size and forecast, by End User
    • 6.4.4.6. Rest of Asia-Pacific
    • 6.4.4.6.1. Market size and forecast, by Type
    • 6.4.4.6.2. Market size and forecast, by End User
• 6.5. LAMEA
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by Type
  • 6.5.3. Market size and forecast, by End User
  • 6.5.4. Market size and forecast, by country
    • 6.5.4.1. Brazil
    • 6.5.4.1.1. Market size and forecast, by Type
    • 6.5.4.1.2. Market size and forecast, by End User
    • 6.5.4.2. Saudi Arabia
    • 6.5.4.2.1. Market size and forecast, by Type
    • 6.5.4.2.2. Market size and forecast, by End User
    • 6.5.4.3. South Africa
    • 6.5.4.3.1. Market size and forecast, by Type
    • 6.5.4.3.2. Market size and forecast, by End User
    • 6.5.4.4. Rest of LAMEA
    • 6.5.4.4.1. Market size and forecast, by Type
    • 6.5.4.4.2. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

• 7.1. Introduction
• 7.2. Top winning strategies
• 7.3. Product mapping of top 10 player
• 7.4. Competitive dashboard
• 7.5. Competitive heatmap
• 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

• 8.1. AstraZeneca plc
  • 8.1.1. Company overview
  • 8.1.2. Key executives
  • 8.1.3. Company snapshot
  • 8.1.4. Operating business segments
  • 8.1.5. Product portfolio
  • 8.1.6. Business performance
  • 8.1.7. Key strategic moves and developments
• 8.2. F. Hoffmann-La Roche Ltd.
  • 8.2.1. Company overview
  • 8.2.2. Key executives
  • 8.2.3. Company snapshot
  • 8.2.4. Operating business segments
  • 8.2.5. Product portfolio
  • 8.2.6. Business performance
• 8.3. GE Healthcare
  • 8.3.1. Company overview
  • 8.3.2. Key executives
  • 8.3.3. Company snapshot
  • 8.3.4. Operating business segments
  • 8.3.5. Product portfolio
  • 8.3.6. Business performance
• 8.4. Boehringer Ingelheim International GmbH
  • 8.4.1. Company overview
  • 8.4.2. Key executives
  • 8.4.3. Company snapshot
  • 8.4.4. Operating business segments
  • 8.4.5. Product portfolio
  • 8.4.6. Business performance
• 8.5. Koninklijke Philips N.V.
  • 8.5.1. Company overview
  • 8.5.2. Key executives
  • 8.5.3. Company snapshot
  • 8.5.4. Operating business segments
  • 8.5.5. Product portfolio
  • 8.5.6. Business performance
  • 8.5.7. Key strategic moves and developments
• 8.6. Abbott Laboratories
  • 8.6.1. Company overview
  • 8.6.2. Key executives
  • 8.6.3. Company snapshot
  • 8.6.4. Operating business segments
  • 8.6.5. Product portfolio
  • 8.6.6. Business performance
• 8.7. Siemens
  • 8.7.1. Company overview
  • 8.7.2. Key executives
  • 8.7.3. Company snapshot
  • 8.7.4. Operating business segments
  • 8.7.5. Product portfolio
  • 8.7.6. Business performance
  • 8.7.7. Key strategic moves and developments
• 8.8. Medtronic plc
  • 8.8.1. Company overview
  • 8.8.2. Key executives
  • 8.8.3. Company snapshot
  • 8.8.4. Operating business segments
  • 8.8.5. Product portfolio
  • 8.8.6. Business performance
• 8.9. Johnson & Johnson
  • 8.9.1. Company overview
  • 8.9.2. Key executives
  • 8.9.3. Company snapshot
  • 8.9.4. Operating business segments
  • 8.9.5. Product portfolio
  • 8.9.6. Business performance
• 8.10. Stryker Corporation.
  • 8.10.1. Company overview
  • 8.10.2. Key executives
  • 8.10.3. Company snapshot
  • 8.10.4. Operating business segments
  • 8.10.5. Product portfolio
  • 8.10.6. Business performance